Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Cryptococcal meningitis

Cryptococcal meningitis

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Cryptococcal meningitis

5 trials tracked for Cryptococcal meningitis: 2 in phase 3 or 4 and 1 with published results. The most-cited published study has 128 citations.

5Trials tracked
2Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 1 Phase 3 1 Phase 2 3
  1. Phase 3 Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis Completed · 128 cited
  2. Phase 4 Cryptococcal Optimal ART Timing Trial Completed
  3. Phase 2 High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals Completed
  4. Phase 2 Optimizing the Dose of Flucytosine for the Treatment of Cryptococcal Meningitis Completed
  5. Phase 2 Amphotericin Alone or in Combination With Fluconazole for AIDS-Associated Meningitis Completed

Showing the 5 most-cited and recently-updated of 5 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Cryptococcal meningitis: what the trials found

Efavirenz treatment in patients with cryptococcal meningitis was associated with a significant reduction in mortality (27 vs 40, p=0.03). However, there were no statistically significant differences observed regarding the incidence of Immune Reconstitution Inflammatory Syndrome (p=0.32) or the incidence of Cryptococcal-relapse (p=0.06).

Sertraline was evaluated for its impact on neurocognitive performance; results showed a Quantitative Neurocognitive Performance Score (QNPZ-8) of -1.4 vs -1.3.

Recent results — preliminary, needs further review

  • The AMBITION trial control is currently being evaluated in Phase 2 studies.
  • Fluconazole was associated with significant differences in the number of participants discontinuing high-dose fluconazole or Ampho B (p=0.0012), categorized quantitative culture results (p=0.012), and changes in log10 quantitative CSF culture results (p=0.019).
  • Amphotericin B was evaluated regarding Grade 3-5 adverse experiences, CSF culture conversion at multiple time points, and mean days of hospitalization.

For the clinician treating this condition

  • Efavirenz is associated with a statistically significant reduction in mortality for patients with cryptococcal meningitis.
  • Sertraline showed no significant difference in neurocognitive performance scores (QNPZ-8) in the studied cohort.

AI synthesis of 0 cited trials, updated Aug 23, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Candidiasis prevalence of 13.46% and Cryptococcal meningitis of 3.15% among HIV-positive individuals
Infectious Disease Meta-analysis
Candidiasis prevalence of 13.46% and Cryptococcal meningitis of 3.15% among HIV-positive individuals New data shows prevalence of fungal infections in HIV patients
This meta-analysis evaluated the prevalence of opportunistic fungal infections in a population of HIV-positive individuals in Ethiopia. The …
New data reveals how common dangerous fungal infections like candidiasis and meningitis are among people living with HIV in Ethiopia.
NEJM Aug 22, 2026